Veterinary pharmaceutical company Parnell Technologies Pty Ltd on Wednesday announced the US launch of nixiFLOR, an injectable solution approved by the US Food and Drug Administration (FDA) for the treatment of bovine respiratory disease and associated fever in beef and non-lactating dairy cattle.

The product is the first FDA-approved generic equivalent of Resflor Gold, containing the same active ingredients, florfenicol and flunixin meglumine.

The FDA determined nixiFLOR to be bioequivalent to Resflor Gold, positioning it as a cost-effective alternative with comparable performance. The therapy combines antimicrobial and anti-inflammatory effects in a single subcutaneous dose, targeting respiratory pathogens while reducing fever.

The single-dose regimen is designed to improve operational efficiency by reducing labour requirements and handling time. As with all florfenicol-based treatments, nixiFLOR is available by prescription and must be administered under veterinary supervision.